Lower-dose GLP-1
MICRODOSING
A lower-dose GLP-1 program, prescribed and dispensed by an independent licensed telehealth network. Your provider decides whether a lower dose is appropriate for you.
Peptides
Coming soon, pending FDA review.
What's in it
Semaglutide Microdose Injection
GLP-1 receptor agonist
· Compounded formulation, not an FDA-approved product · GLP-1 receptor agonist · Provider-selected and dose-titrated · Weekly subcutaneous injection
Tirzepatide Microdose Injection
Dual GIP and GLP-1 receptor agonist
· Compounded formulation, not an FDA-approved product · GIP and GLP-1 receptor agonist · Provider-selected and dose-titrated · Weekly subcutaneous injection
Complete your intake. Five minutes, HIPAA-secure. Your medical history, current medications, and what you are trying to achieve.
Independent provider review. A licensed telehealth provider reviews your intake, exercises clinical judgment, and prescribes if appropriate. Never your surgeon.
If prescribed, compounded and shipped. Your medication is compounded by an independent FDA-registered pharmacy and shipped directly, with check-ins as your provider directs.
- Adults whose provider determines that GLP-1 therapy is clinically appropriate
- Individuals who have tried diet and exercise alone without sustained results
- People looking for a physician-supervised alternative to over-the-counter weight loss products
No. These are compounded formulations. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it has stated that some compounded semaglutide products use salt forms that are different active ingredients from those in the approved drugs.
In SURMOUNT-1, branded injectable tirzepatide at 5, 10 and 15 milligrams produced mean body-weight reductions of 15.0, 19.5 and 20.9 percent over 72 weeks, compared with 3.1 percent for placebo (Jastreboff et al., New England Journal of Medicine, 2022). In STEP-1, branded injectable semaglutide at 2.4 milligrams weekly produced a mean reduction of 14.9 percent over 68 weeks, compared with 2.4 percent for placebo (Wilding et al., New England Journal of Medicine, 2021). In OASIS-4, branded oral semaglutide at 25 milligrams daily produced a mean reduction of 13.6 percent at week 64, compared with 2.2 percent for placebo (Wharton et al., New England Journal of Medicine, 2025).
These trials studied full approved doses of branded products. This program dispenses lower doses of compounded formulations, and no trial result describes what is dispensed here.
Reduced appetite
GLP-1 receptor agonists act on appetite signalling and slow gastric emptying. Your individual response is determined by your provider and your own physiology.
Ongoing clinical oversight
Your provider monitors your response at regular check-ins and adjusts your dose.
- Licensed provider consultation and prescription
- Compounded medication shipped to your door
- Personalized dosing protocol
- Regular provider check-ins and monitoring
- Secure messaging with your care team
What does microdosing mean here?
It means a lower dose of the same GLP-1 medications used in the full-dose programs. It does not mean a different medication, and it is not a claim that a lower dose works better or suits people a standard dose does not. Your provider decides the starting dose and any change to it.
How does a provider decide whether a lower dose is appropriate?
The provider reviews your history, your current medications, your tolerance of previous therapy if you have had any, and what you are trying to achieve. Dosing is a clinical judgment made for you, not a product you select.
Is this FDA-approved?
No. These are compounded formulations. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it has stated that some compounded semaglutide products use salt forms that are different active ingredients from those in the approved drugs. Published trial results for the branded products do not describe what is dispensed here.
What are the side effects?
The FDA labels for the branded GLP-1 medications list nausea, diarrhea, vomiting, constipation and abdominal pain among the most common adverse reactions. Your provider screens at intake for contraindications, including a personal or family history of medullary thyroid carcinoma or MEN2 and prior serious hypersensitivity to the medication, and for warnings, including a history of pancreatitis.
How is this different from the weight loss program?
It uses the same class of medication at a lower dose, on a separate program. Which one fits you is a clinical decision, and your provider will tell you if a different program is more appropriate.
Peptides
Coming soon, pending FDA review.